Neuro Drugs are Still Faltering, Despite Rising Investment

28bio announces the 2026 recipients of the 28bioGRANT for Neurodegenerative Disease, supporting innovative research in CNS-targeted nanotherapeutics and human iPSC-based Alzheimer’s disease modeling.

The 28bioGRANT for Neurodegenerative Disease is designed to assist academic researchers in their pursuit to understand the human biological underpinnings of these diseases and translate those insights into potential therapeutic strategies.